Clinical evaluation of extract of Cajanus cajan (Ciklavit®) in sickle cell anaemia

Journal of Tropical Pediatrics

Volumn 51, Issue 4, 2005, Pages 200-205

  Akinsulie, A O ^a   Temiye, Eda O ^a   Akanmu, A S ^a   Lesi, F E A ^a   Whyte, C O ^a  

^a UNIVERSITY OF LAGOS   (Nigeria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISICKLING AGENT; ASCORBIC ACID; BILIRUBIN; CAJANUS CAJAN EXTRACT; CIKLAVIT; CREATININE; FOLIC ACID; PLACEBO; PLANT EXTRACT; PROGUANIL; PYRIMETHAMINE; UNCLASSIFIED DRUG; UREA; ZINC; PLANT MEDICINAL PRODUCT;

ABDOMINAL DISTENSION; ARTICLE; BILIRUBIN BLOOD LEVEL; BODY WEIGHT; CHILD; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; FATIGUE; FEMALE; HEMATOCRIT; HEPATOMEGALY; HEPATOSPLENOMEGALY; HUMAN; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; OCULAR PRURITUS; ORBIT INFLAMMATION; PAIN ASSESSMENT; PIGEONPEA; RANDOMIZED CONTROLLED TRIAL; SICKLE CELL ANEMIA; SICKLE CELL TRAIT; SINGLE BLIND PROCEDURE; UREA BLOOD LEVEL; VOMITING; ADOLESCENT; ANALYSIS OF VARIANCE; DRUG EFFECT; INFANT; LIVER; PHYTOTHERAPY; PRESCHOOL CHILD;

ADOLESCENT; ANALYSIS OF VARIANCE; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; CAJANUS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; LIVER; MALE; PHYTOTHERAPY; PLANT PREPARATIONS; SINGLE-BLIND METHOD;

EID: 25644442481     PISSN: 01426338     EISSN: 14653664     Source Type: Journal    
DOI: 10.1093/tropej/fmh097     Document Type: Article

References (24)

1. Goldberg MA, Brugnara C, Dover GJ, Schapira L, Charache S, Bunn HF. Treatment of sickle cell anemia with hydroxyurea and erythropoietin. N Engl J Med 1990; 323: 366-72.
2. De Franceschi L, Bachir D, Galacteros F, et al. Oral magnesium supplements reduce erythrocyte dehydration in patents with sickle cell disease. J Clin Invest 1997; 100: 1847-52.
3. Brugnara C, Gee B, Armsby CC, et al. Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patents with sickle cell disease. J Clin Invest 1996; 97: 1227-34.
4. Brewer GJ, Brewer LF, Prasad AS. Suppression of irreversibly sickled erythrocytes by zinc therapy in sickle cell anemia. J Lab Clin Med 1997; 90: 549-54.
5. Jaja SI, Kehinde MO, Gbenebitse S, Mojiminiyi FBO, Ogungbemi AI. Effect of vitamin C on arterial blood pressure, irreversibly sickled cells and osmotic fragility in sickle cell anemia subjects. Nigerian. J Physiol Sci 2000; 16: 14-8.
6. Natta CL, Machlin LJ, Brin M. A decrease in irreversibly sickled erythrocytes in sickle cell anemia patients given vitamin E. Am J Clin Nutr 1980; 33: 968.
7. Cerami A, Manning JM. Potassium cyanate as an inhibitor of the sickling of erythrocytes in vitro. Proc Nat Acad Sci USA 1971; 68: 1180-83.
8. Morris CR, Kuypers FA, Larkin S, et al. Arginine therapy: A novel strategy to induce nitric oxide production in sickle cell disease. Br J Haematol 2000; 111: 498-500.
9. Noguchi CT, Schechter AN. Effects of amino acids on gelation kinetics and solubility of sickle hemoglobin. Biochem Biophys Res Comm 1977; 74: 634-42.
10. Epstein FH. Pathogenesis and treatment of sickle cell disease. N Engl J Med 1997; 337: 762-69.
11. Harkness DR, Roth S. Clinical evaluation of cyanate in sickle cell anaemia. Progress Haematol 1975; 9: 157-84.
12. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyuria on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995; 332: 1317-22.
13. Cajanus cajan Millsp. African Pharmacopoeia; Vol. 1: OAU/STRC Scientific Publications, Lagos, Nigeria, 1985; 35-7.
14. Olatunji-Bello II, Obijeih TA, Mojiminiyi FBO. Tocolytic effect of Cajanus cajan (in-vitro studies using the rat uterus). Nigerian Quarterly J Hosp Med 2000; 10: 278-81.
15. Ekeke GI, Shode FO. The reversion of sickled cells by Cajanus cajan Planta Medica 1985; 51: 504-07.
16. Ekeke GI, Shode FO. Phenylalanine is the predominant antisickling agent in Cajanus cajan seed extract. Planta Medica 1990; 56: 41-3.
17. Jaja SI, Ikotun AR, Gbenebitse S, Temiye EO. Blood pressure, hematologic and eythrocyte fragility changes in children suffering from sickle cell anemia following ascorbic acid supplementation. J Trop Pediatr 2002; 48: 366-69.
18. Brewer GJ, Bereza U. Membrane therapy of sickle cell anemia with zinc and other drugs. In: Fried W (ed.), Comparative Clinical Aspects of Sickle Cell Disease. Elsevier, North Holland Inc., 1982; 175-87.
19. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease: Rates and risk factors. N Engl J Med 1991; 325: 11-6.
20. Baum KF, Dunn DT, Maude GH, Serjeant GR. The painful crisis of homozygous sickle cell disease: A study of risk factors. Arch Intern Med 1987; 147: 1231-34.
21. Lande WM, Andrews DL, Clark MR, et al. The incidence of painful crisis in homozygous sickle cell disease: Correlation with red cell deformability. Blood 1988; 72: 2056-59.
22. Rosenblate HJ, Eisenstein R, Holmes AW. The liver in sickle cell anemia: a clinical-pathologic study. Arch Path 1970; 90: 235-45.
23. Serjeant GR. The liver. Sickle Cell Disease. Oxford University Press, New York, 1985; 100-07.
24. Iwu MM, Igboko OA, Onwubiko H, Ndu UE. Anti-sickling properties of Cajanus cajan: Effect on haemoglobin gelation and oxygen affinity. Planta Medica 1986; 52: 431-32.